These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 32941917)

  • 1. Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations.
    Le Duff F; Bouaziz JD; Fontas E; Ticchioni M; Viguier M; Dereure O; Reygagne P; Montaudié H; Lacour JP; Monestier S; Richard MA; Passeron T
    J Invest Dermatol; 2021 Apr; 141(4):933-936.e6. PubMed ID: 32941917
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety.
    Lai VWY; Chen G; Gin D; Sinclair R
    J Am Acad Dermatol; 2019 Sep; 81(3):694-701. PubMed ID: 31048013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata.
    Castela E; Le Duff F; Butori C; Ticchioni M; Hofman P; Bahadoran P; Lacour JP; Passeron T
    JAMA Dermatol; 2014 Jul; 150(7):748-51. PubMed ID: 24872229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.
    Shah MH; Freud AG; Benson DM; Ferkitich AK; Dezube BJ; Bernstein ZP; Caligiuri MA
    Clin Cancer Res; 2006 Jul; 12(13):3993-6. PubMed ID: 16818697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study.
    Strober BE; Menon K; McMichael A; Hordinsky M; Krueger G; Panko J; Siu K; Lustgarten JL; Ross EK; Shapiro J
    Arch Dermatol; 2009 Nov; 145(11):1262-6. PubMed ID: 19917955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of persistent alopecia areata with sulfasalazine.
    Rashidi T; Mahd AA
    Int J Dermatol; 2008 Aug; 47(8):850-2. PubMed ID: 18717871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose interleukin 2 to reverse alopecia areata.
    Hordinsky M; Kaplan DH
    JAMA Dermatol; 2014 Jul; 150(7):696-7. PubMed ID: 24870927
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of platelet-rich plasma on hair regrowth and lesional T-cell cytokine expression in alopecia areata: A randomized observer-blinded, placebo-controlled, split-head pilot study.
    Gupta V; Parihar AS; Sharma VK; Jain S; Singh V; Khanna N
    J Am Acad Dermatol; 2021 May; 84(5):1321-1328. PubMed ID: 33359595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib for the treatment of severe alopecia areata.
    Liu LY; King BA
    J Am Acad Dermatol; 2019 Feb; 80(2):566-568. PubMed ID: 30195572
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata.
    Guttman-Yassky E; Nia JK; Hashim PW; Mansouri Y; Alia E; Taliercio M; Desai PN; Lebwohl MG
    Arch Dermatol Res; 2018 Oct; 310(8):607-614. PubMed ID: 30121698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic alopecia areata with tildrakizumab: an open-label pilot study.
    Kerkemeyer KLS; Sinclair R
    Int J Dermatol; 2020 May; 59(5):e136-e137. PubMed ID: 32124974
    [No Abstract]   [Full Text] [Related]  

  • 12. An open-label study evaluating the efficacy of abatacept in alopecia areata.
    Mackay-Wiggan J; Sallee BN; Wang EHC; Sansaricq F; Nguyen N; Kim C; Chen JC; Christiano AM; Clynes R
    J Am Acad Dermatol; 2021 Mar; 84(3):841-844. PubMed ID: 33045294
    [No Abstract]   [Full Text] [Related]  

  • 13. [Significance of HLA-DR+ T cells and natural killer (NK) cells in the peripheral blood lymphocytes of alopecia areata (AA)].
    Imai R
    Nihon Hifuka Gakkai Zasshi; 1990 Oct; 100(11):1143-52. PubMed ID: 2273577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of efficacy of apremilast in 9 patients with severe alopecia areata.
    Liu LY; King BA
    J Am Acad Dermatol; 2017 Oct; 77(4):773-774. PubMed ID: 28917463
    [No Abstract]   [Full Text] [Related]  

  • 15. Complex Interaction Between Diphenylcyclopropenone and Immune Responses in Alopecia Areata.
    Tavakolpour S; Mahmoudi HR; Daneshpazhooh M; Rahimzadeh G
    Scand J Immunol; 2016 Nov; 84(5):310-311. PubMed ID: 27500683
    [No Abstract]   [Full Text] [Related]  

  • 16. Alopecia areata predictive score: A new trichoscopy-based tool to predict treatment outcome in patients with patchy alopecia areata.
    Waśkiel-Burnat A; Rakowska A; Sikora M; Olszewska M; Rudnicka L
    J Cosmet Dermatol; 2020 Mar; 19(3):746-751. PubMed ID: 31301100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alopecia areata: a review of disease pathogenesis.
    Rajabi F; Drake LA; Senna MM; Rezaei N
    Br J Dermatol; 2018 Nov; 179(5):1033-1048. PubMed ID: 29791718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin A and alopecia areata.
    Moreno JC; Ocaña MS; Vélez A
    J Eur Acad Dermatol Venereol; 2002 Jul; 16(4):417-8. PubMed ID: 12224710
    [No Abstract]   [Full Text] [Related]  

  • 19. Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: An intrasubject pilot study.
    Chu TW; AlJasser M; Alharbi A; Abahussein O; McElwee K; Shapiro J
    J Am Acad Dermatol; 2015 Aug; 73(2):338-40. PubMed ID: 26183987
    [No Abstract]   [Full Text] [Related]  

  • 20. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
    Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
    Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.